Secukinumab therapy for paediatric patients with various phenotypes of congenital ichthyosis

Abstract

This case series demonstrates that secukinumab therapy for paediatric patients with congenital ichthyosis is safe and has variable efficacy, similar to results from clinical trials in adults. A good response is seen in patients with the erythrodermic phenotypes, namely congenital ichthyosiform erythroderma and Netherton syndrome, with a minor response seen in lamellar ichthyosis phenotypes. Clinical data are overall lacking for the paediatric population, and this study adds some insights to the existing research.